What is Profusa, Inc. Common Stock?
develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States.
PFSA · Verdict
Limited reward · high risk
PFSA's standout is volatility; cash flow and balance sheet weigh on the picture.
Based on 88% data coverage
PFSA · Verdict
Above average
Weak vs peers
Current ratio 0.00
0% return on equity
Earnings -3.6% CAGR
Model-based scoring. For information only — not financial advice.
develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.71M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.